[HTML][HTML] Genetic evaluation of inpatient neonatal and infantile congenital heart defects: new findings and review of the literature

BM Helm, BJ Landis, SM Ware - Genes, 2021 - mdpi.com
BM Helm, BJ Landis, SM Ware
Genes, 2021mdpi.com
The use of clinical genetics evaluations and testing for infants with congenital heart defects
(CHDs) is subject to practice variation. This single-institution cross-sectional study of all
inpatient infants with severe CHDs evaluated 440 patients using a cardiovascular genetics
service (2014–2019). In total, 376 (85.5%) had chromosome microarray (CMA), of which 55
(14.6%) were diagnostic in syndromic (N= 35) or isolated (N= 20) presentations. Genetic
diagnoses were made in all CHD classes. Diagnostic yield was higher in syndromic …
The use of clinical genetics evaluations and testing for infants with congenital heart defects (CHDs) is subject to practice variation. This single-institution cross-sectional study of all inpatient infants with severe CHDs evaluated 440 patients using a cardiovascular genetics service (2014–2019). In total, 376 (85.5%) had chromosome microarray (CMA), of which 55 (14.6%) were diagnostic in syndromic (N = 35) or isolated (N = 20) presentations. Genetic diagnoses were made in all CHD classes. Diagnostic yield was higher in syndromic appearing infants, but geneticists’ dysmorphology exams lacked complete sensitivity and 6.5% of isolated CHD cases had diagnostic CMA. Interestingly, diagnostic results (15.8%) in left ventricular outflow tract obstruction (LVOTO) defects occurred most often in patients with isolated CHD. Geneticists’ evaluations were particularly important for second-tier molecular testing (10.5% test-specific yield), bringing the overall genetic testing yield to 17%. We assess these results in the context of previous studies. Cumulative evidence provides a rationale for comprehensive, standardized genetic evaluation in infants with severe CHDs regardless of lesion or extracardiac anomalies because genetic diagnoses that impact care are easily missed. These findings support routine CMA testing in infants with severe CHDs and underscore the importance of copy-number analysis with newer testing strategies such as exome and genome sequencing.
MDPI